Second-line afatinib vs erlotinib for patients with squamous cell carcinoma of the lung in LUX-Lung 8: analysis of tumor and serum biomarkers

Lee, K. H.Soria, J-C.Felip, E.Cobo, M.Lu, S.Syrigos, K.Goker, E.Georgoulias, V.Li, W.Guclu, S.Isla, D.Ardizzoni, A.Gadgeel, S. M.Dupuis, N.Gibson, N. J.Kramer, N.Buehnemann, C.Solca, F.Ehrnrooth, E.Goss, G.2019-10-272019-10-2720160923-75341569-8041https://hdl.handle.net/11454/33187eninfo:eu-repo/semantics/closedAccessSecond-line afatinib vs erlotinib for patients with squamous cell carcinoma of the lung in LUX-Lung 8: analysis of tumor and serum biomarkersConference Object27WOS:000393980600445Q1